Have a feature idea you'd love to see implemented?
Let us know!
TMDX TransMedics Group Inc
Price (delayed)
$79.34
Market cap
$2.66B
P/E Ratio
80.14
Dividend/share
N/A
EPS
$0.99
Enterprise value
$2.85B
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need
Highlights
TransMedics Group's EPS has surged by 191% YoY
The net income has soared by 191% YoY
The quick ratio has contracted by 29% YoY and by 14% from the previous quarter
The gross margin has contracted by 10% YoY and by 2.3% from the previous quarter
Key stats
What are the main financial stats of TMDX
Market
Valuations
Earnings
Shares outstanding
33.56M
Market cap
$2.66B
Enterprise value
$2.85B
Price to earnings (P/E)
80.14
Price to book (P/B)
12.61
Price to sales (P/S)
6.62
EV/EBIT
60.52
EV/EBITDA
43.06
EV/Sales
7.11
Revenue
$401.09M
EBIT
$47.1M
EBITDA
$66.2M
Free cash flow
-$120.51M
Per share
Balance sheet
Liquidity
EPS
$0.99
Free cash flow per share
-$3.6
Book value per share
$6.29
Revenue per share
$11.99
TBVPS
$23.08
Total assets
$785.57M
Total liabilities
$575.65M
Debt
$518.15M
Equity
$209.92M
Working capital
$432.43M
Debt to equity
2.47
Current ratio
8.2
Quick ratio
7.01
Net debt/EBITDA
2.83
Margins
Efficiency
Dividend
EBITDA margin
16.5%
Gross margin
59.3%
Net margin
8.1%
Operating margin
7.8%
Return on assets
4.4%
Return on equity
18.7%
Return on invested capital
5.7%
Return on capital employed
6.5%
Return on sales
11.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TMDX stock price
How has the TransMedics Group stock price performed over time
Intraday
2.77%
1 week
-10.21%
1 month
-36.26%
1 year
16.87%
YTD
0.52%
QTD
-49.46%
Financial performance
How have TransMedics Group's revenue and profit performed over time
Revenue
$401.09M
Gross profit
$237.99M
Operating income
$31.46M
Net income
$32.64M
Gross margin
59.3%
Net margin
8.1%
The net income has soared by 191% YoY
TMDX's operating income has soared by 183% YoY
The company's net margin has surged by 143% YoY
The operating margin has surged by 139% year-on-year
Growth
What is TransMedics Group's growth rate over time
Valuation
What is TransMedics Group stock price valuation
P/E
80.14
P/B
12.61
P/S
6.62
EV/EBIT
60.52
EV/EBITDA
43.06
EV/Sales
7.11
TransMedics Group's EPS has surged by 191% YoY
TMDX's equity has surged by 66% year-on-year and by 11% since the previous quarter
The stock's P/B is 41% less than its last 4 quarters average of 21.3 but 3.4% more than its 5-year quarterly average of 12.2
The revenue has soared by 109% YoY and by 12% from the previous quarter
The P/S is 64% lower than the 5-year quarterly average of 18.3 and 42% lower than the last 4 quarters average of 11.4
Efficiency
How efficient is TransMedics Group business performance
TransMedics Group's return on equity has surged by 185% YoY
The ROIC has soared by 185% from the previous quarter and by 176% YoY
TransMedics Group's return on sales has surged by 177% YoY and by 166% QoQ
The ROA has soared by 159% year-on-year
Dividends
What is TMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TMDX.
Financial health
How did TransMedics Group financials performed over time
The total assets is 36% more than the total liabilities
The quick ratio has contracted by 29% YoY and by 14% from the previous quarter
The company's current ratio fell by 25% YoY and by 12% QoQ
The company's debt is 147% higher than its equity
TMDX's equity has surged by 66% year-on-year and by 11% since the previous quarter
TMDX's debt to equity is down by 39% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.